NCT04638790View on ClinicalTrials.gov

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Hodgkin Lymphoma, Adult
Interventions
DRUG

Doxorubicin

25 mg/m2 i.v. day 1,15 for ABVD/AVD

DRUG

Bleomycin

10,000 units/m2 i.v. days 1,15 for ABVD

DRUG

Vinblastine

6 mg/m2 i.v. days 1,15 for ABVD/AVD

DRUG

Dacarbazine

375 mg/m2 i.v. days 1,15 for ABVD/AVD

DRUG

Etoposide

100 mg/m2 i.v. days 1-3

DRUG

Doxorubicin

50 mg/m2 i.v. day 1 for EACODD-14

DRUG

Cyclophosphamide

650 mg/m2 i.v. day 1

DRUG

Vincristine

1,4 mg/m2 i.v. day 8

DRUG

Dexamethasone

20 mg i.v. days 1-3

DRUG

Dacarbazine

375 mg/m2 i.v. day 1 for EACODD-14

Trial Locations (2)

105203

RECRUITING

The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow

Unknown

RECRUITING

Tata Memorial Hospital, Mumbai

All Listed Sponsors
lead

State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

OTHER

NCT04638790 - First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) | Biotech Hunter | Biotech Hunter